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Abstract
Mass spectrometry as an instrument is popular, given its sensitivity, selectivity, 
speed and robustness. In this chapter, we have briefly deliberated on various mass 
spec platforms, their hardware components and specific applications in preclinical 
drug discovery with a special emphasis on drug metabolism and pharmacokinetic 
assays. Basic principle of operation of mass spectrometer and various ionization 
techniques/mass analyzers was explicitly discussed. Compatibility of mass spec-
trometers with ultrafast LC and various throughput techniques, enabled evaluation 
of thousands of compounds with quick turnaround times. Faster generation of 
results corresponding to in vitro ADME and in vivo pharmacokinetic assays, aid 
medicinal chemists to refine their combinatorial synthetic chemistry efforts and 
expedite the lead optimization and identification phases of drug discovery. Mass 
spectrometer is a powerful tool for both qualitative and quantitative applications. 
While quantitative applications include measurement of absolute/relative con-
centrations, qualitative features assist in identification of molecular structures of 
metabolites and putative biotransformation pathways. Qualitative inputs are more 
precise and accurate, with the advent of high-resolution mass spectrometry tech-
nology. Although, mass spectrometry has many built-in advantages, it also suffers 
from matrix effects, as the samples analyzed are mostly of biological origin and are 
complex in nature. In this chapter, we have defined the nature of matrix effects and 
various approaches by which these matrix effects can be mitigated.
Keywords: mass spectrometer, mass analyzers, ionization sources, DMPK, ADME, 
LC–MS/MS, matrix effects
1. Introduction
Since its discovery 100 years ago by Sir J.J. Thompson for the quantitative 
measurement of the mass and charge of cathode rays, mass spectrometer eventually 
evolved as a reliable analytical platform aimed at the analysis of small and large 
molecules [1]. While hyphenation of mass spectrometry with gas chromatogra-
phy achieved its early success, however, liquid chromatography could not due to 
indigent mass spec interfaces. This is given the inability of interfaces to handle 
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higher flow rates of liquid sample. Additionally, ionization techniques such as 
chemical and electron impact ionization did not suit for thermolabile and high 
molecular weight compounds [2, 3]. Advancement in ionization techniques such 
as fast atom bombardment that suited for analysis of large molecules, thermospray 
and particle beam ionization which were efficient for small molecules enabled the 
fruitful hyphenation of liquid chromatography with mass spectrometry [4–7]. 
Thermospray in general forms ammonium adducts, while particle beam gener-
ated electron impact spectra. Within a few years thermospray was succeeded by 
atmospheric pressure ionization techniques such electrospray ionization (ESI), 
atmospheric pressure chemical ionization (APCI), atmospheric pressure photoion-
ization (APPI) and atmospheric pressure matrix assisted laser desorption ionization 
(AP-MALDI). Mass spectrometer operates on the principle of ionization of analytes 
followed by their separation based on their mass-to-charge ratio [8]. Various mass 
spectrometer analyzers ranging from linear trap, ion trap, triple quadrupole, time 
of flight and orbitrap have specific applications for sample analysis in preclinical 
drug discovery and development.
Medicinal chemistry efforts in drug discovery is majorly focused on understand-
ing the right combination of new chemical entity (NCE) properties that helps in 
cherry-picking the compounds with promising properties to progress from discov-
ery to development phase. In the process of lead optimization, NCE’s are subjected 
to a series of drug metabolism and pharmacokinetic assays to assess the druggable 
properties and mitigate late stage failures. Almost 40% of failures in development 
phase were due to poor pharmacokinetic properties of NCE’s [9]. However, this 
percentage had gradually decreased to 10% as major pharmaceutical companies 
incorporated drug metabolism and pharmacokinetic screening (DMPK) in lead 
optimization phase of drug discovery. In this view, compounds must pass through 
a series of screens that scrutinize the problematic compounds until a small number 
have been selected for more rigorous testing in the development phase. Hence, lead 
optimization typically is an iterative process that uses the DMPK data to optimize 
the druggable properties of NCE’s. Regardless of the screening panel, qualita-
tive and quantitative analytical results to understand absorption, distribution, 
metabolism and excretion (ADME) properties were generated using liquid chro-
matography–tandem mass spectrometry (LC–MS/MS) [10–17]. In this chapter, we 
have briefly discussed on various atmospheric pressure ionization techniques/mass 
analyzers, and applications of mass spectrometer in drug discovery with special 
emphasis on drug metabolism and pharmacokinetic assays.
2. Atmospheric pressure ionization
Ionization in atmospheric ionization sources occur at atmospheric pressure and 
ions then gets transferred into the vacuum. As the liquid completely converts in to 
gas phase in the ionization source, those ionization techniques that use atmospheric 
pressure ionization are more convenient to hyphenate with liquid chromatography. 
These ionization techniques include electrospray ionization (ESI), atmospheric 
pressure chemical ionization (APCI), and atmospheric pressure photoionization 
(APPI) and are most widely used. Additionally, MALDI that also uses atmospheric 
pressure ionization is getting popular with its unique feature in performing mass 
spectrometry imaging (MSI) and analysis of large molecules [18]. Also, other 
ionization techniques such as desorption electrospray (DESI) or direct analysis in 
real time (DART) are becoming popular for the analysis of surface or solid samples 
[19, 20]. However, their applications in the field of drug metabolism and pharmaco-
kinetics are very limited.
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2.1 Electrospray ionization (ESI)
In ESI, analytes initially get charged with the assistance of electrical energy 
and charged ions transfer from solution to gaseous phase, before subjecting to 
mass spectrometric analysis. Ionic species in solution can be analyzed as such, 
whereas neutral compounds can be converted to ionic species and studied by 
ESI-MS. Electrospray ionization occurs in four stages: 1) charging of analytes in the 
capillary tube 2) formation of fine spray of charged droplets 3) solvent evaporation 
4) columbic explosion/Rayleigh scattering of ions from the droplet (Figure 1). 
The liquid effluent moves from liquid chromatography to the mass spectrometer 
through a fused silica capillary maintained at voltage of 2.5–6.0 KV. In negative 
mode, to avoid discharge the range is lower (3–4 KV) than positive mode. ESI is 
a condensed phase ionization process and the ions have to be already present in 
solution. To generate ions, the pH has to be adjusted in such a way that ionizable 
groups are either protonated or deprotonated. In some cases, neutral molecules can 
be analyzed by the formation of adducts with ions such as ammonium, sodium, 
potassium, acetate or silver. Charged droplets undergo nebulization in the presence 
of nebulizer gas. After nebulization, charged droplets further reduce in size with 
the assistance of heat and breakdown in to minute droplets. Finally, as the droplets 
grow smaller and smaller, ions get released in to gaseous phase by a mechanism 
called rayleigh scattering/columbic explosion. The emitted ions are sampled by a 
sampling skimmer cone and are then accelerated into the mass analyzer for sub-
sequent measurement of molecular mass and ion intensity [21–24]. An important 
characteristic of ESI-MS is it works as a concentration-dependent detector, which 
means MS response is directly proportional to concentration of analyte. Hence, 
irrespective of flow rate of mobile phase post column to the ionization source, 
response remains the same as long as the source-gas conditions are optimal for the 
flow rate. ESI technique is suitable for the analysis of polar to moderately polar 
molecules.
2.2 Atmospheric pressure chemical ionization (APCI)
In atmospheric pressure chemical ionization, unlike ESI, sample evaporation 
occurs first, followed by ionization in gas phase through corona discharge needle 
(Figure 2) [25]. The ionization principle is mostly similar to chemical ionization; 
however, it occurs at atmospheric pressure. APCI-MS can also be called as mass-
sensitive detector, as the higher flow that goes in to ionization source, the higher will 
Figure 1. 
Mechanism of electrospray ionization process.
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Figure 2. 
Mechanism of atmospheric pressure chemical ionization process.
be the peak response. One important requirement in APCI for optimal sensitivity is 
the sample has to be completely evaporated, before subjecting to ionization. First an 
aerosol of mobile phase is formed with the assistance of nebulizer gas. This aerosol 
is further subjected to heating at 200–550°C in a ceramic tube enabling complete 
evaporation. Even though higher temperatures are employed, the actual tempera-
ture felt by analyte molecules is way lesser due to a phenomenon called evaporative 
cooling effect/evaporation enthalpy. Next, analyte molecules in gas phases were 
bombarded with electrons formed from corona discharge needle [26, 27]. In positive 
mode primary ions such as N2+ are formed by electron impact. These ions further 
react with water in several steps by charge transfer to form H3O+. Ionization of the 
analytes occurs then by proton transfer from H3O+. In negative mode ions are formed 
either by: (i) resonance capture (AB to AB−), (ii) dissociative capture (AB to B−) or 
(iii) ion–molecule reaction (BH to B−). One disadvantage with APCI when compared 
to ESI is, APCI is not suitable for thermolabile compounds as typical temperatures 
experienced by the analyte molecules are ~150°C. However, in case of ESI, molecules 
encounter temperatures ~40°C in the process of evaporation.
2.3 Atmospheric pressure photo ionization (APPI)
APPI by design is similar to APCI, with only difference being the replacement of 
corona discharge needle with gas discharge krypton lamp (10.0 eV) that produces 
ultraviolet photons [28–30]. Evaporation of liquid phase happens in pneumatic 
nebulizer. While ionization potential for most of the analytes is less than 10 eV; 
mobile phase constituents such as water, acetonitrile and methanol has higher 
potential requirements. Presence of dopants such as toluene or acetone will help in 
enhancing the sensitivity of analyte ions. Dopant molecules absorb photon energy 
and eject an electron, resulting in the formation of radical cation. Ionization of 
analytes can happen by two processes: 1) Charge transfer between analyte and 
radical cations generated from dopant molecules. 2) Charge transfer between 
dopant molecules and mobile phase components and finally from mobile phase 
components to analytes (Figure 3). Similar to other atmospheric pressure ioniza-
tion techniques, APPI is also suitable for negative mode of ionization. Sensitivity 
of APPI is flow rate dependent and better sensitivities have been reported at low 
flow rates. When compared to APCI, APPI offers lesser matrix effects and minimal 
source contamination. Success of APPI as an ionization technique was reported in 
the analysis of steroids and quinones [31–33].
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In a nut shell, ESI is useful for the analysis of moderately polar to highly polar 
analytes; APCI covers moderately polar to non-polar analytes, whereas APPI suits 
for non-polar to moderately polar analytes.
2.4 Matrix assisted laser desorption ionization (MALDI)
MALDI operates on principle of ionization of analytes dissolved in a matrix 
consisting of organic compound (sinapinic acid, α-cyano-4-hydroxycinnamic acid, 
2,5-dihydroxybenzoic acid) and evaporated to dryness on a target plate [34]. Matrix 
crystallizes up on drying and the analyte dissolved with in it also gets co-crystal-
lized. Firstly, laser beam hits the dried sample and ionize organic compound, which 
later ionize the analyte molecules. Laser beam causes both desorption and ioniza-
tion of analytes. Nitrogen laser emitting at 337 nm and Nd: YAG laser emitting at 
355 nm are the most widely used ones (Figure 4). MALDI is considered as a very 
Figure 3. 
Schematic representation of atmospheric pressure photo ionization process.
Figure 4. 
Mechanism of matrix assisted laser desorption ionization process.
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soft ionization technique that causes minimal fragmentation of the analyte ions and 
is also suitable for analysis of large molecules ranging from peptides to proteins, lip-
ids and polymers [35–38]. It is also amenable to high throughput and target sample 
plates can be readily stored for future use. One major advantage of MALDI-MS is 
chromatographic separation of analytes is not required. However, due to lack of 
separation, matrix interferences impact the analytical results [39, 40]. Additionally, 
MALDI is not suitable for low molecular weight compounds. Also, MALDI needs 
TOF as an analyzer to cover high mass range in a linear mode, whereas ESI can 
be coupled with any mass analyzer. Recently, MALDI has been coupled to triple 
quadrupole and successfully used for the analysis of small molecules [41, 42].
3. Mass analyzers
3.1 Quadrupole analyzer
Quadrupole mass analyzer consists of four hyperbolic or circular rods positioned 
in parallel and are located diagonally at identical distances from each other. The 
rods are diagonally connected. Positive direct current (DC; U) is applied to one pair 
of rods and negative potential is applied to the other pair of rods. Apart from direct 
current, alternating radiofrequency (RF; Vcos ωt) potential is also applied to these 
rods. The ion trajectory is affected in x and y directions by the total electric field 
composed by a quadrupolar alternating field and a constant field. Because there 
is only a two-dimensional quadrupole field the ions accelerated after ionization, 
maintain their velocity along the z axis.
The motion of ions in the quadrupole can be best described by Mathieu 
Equations [43]. The ions supposedly travel in a stable trajectory and only those 
ions that travel in stable trajectory reaches detector. Mass spectrum is obtained by 
ramping RF and DC voltages in a constant ratio. When DC voltage is set to zero and 
RF voltage is maintained, all ions pass through quadrupole. It is the DC voltage that 
helps in filtering out the ions of interest and generate mass spectrum (Figure 5). 
Hence, the quadrupoles that apply only RF voltages just act as ion guides or collision 
cell. Mass resolution for typical quadrupole analyzers falls in the range 0.6–0.8 da 
units, which is defined to be a unit resolution. However, current generation high 
resolution mass spectrometers offer to determine masses within 5–10 ppm error.
3.2 Triple quadrupole mass analyzer
Triple quadrupole mass analyzer consists of two RF/DC mass analyzers and two 
RF only mass analyzers. Q0and Q2 (collision cell) were considered to be RF only 
quadrupoles, whereas Q1 and Q3 falls under RF/DC mass analyzers [44]. Hence, Q0 
and Q2 acts as ion guides and Q1 and Q3 acts as mass filters. Q0 acts as an ion guide 
by focusing all the ions obtained from ionization source to Q1. Q1 even though a RF/
DC mass analyzer, can also be operated in RF only quadrupole depending on the 
type of analysis. When it comes to qualitative analysis, Q1 acts as a RF only quadru-
pole, whereas in case of quantitative analysis it acts as RF/DC quadrupole. Similarly, 
Q3 also operates in both modes based on the analytical requirements. Q2 in addition 
being a RF only quadrupole, acts as a collision cell to fragment the ions and generate 
compound specific information, which enables the mass spec to be a more specific 
and selective detection system (Figure 6). Process of generation of fragment ions in 
the collision cell is termed as collision induced dissociation (CID), which happens 
with the assistance of neutral argon or nitrogen gas [45, 46].
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Based on the modes in which the mass analyzers are operated and the analytical 
requirements, they can be briefly classified as below:
While full scan modes are useful in understanding the total pool of masses pres-
ent in the sample analyzed, product ion scan helps in obtaining structural informa-
tion of a precursor ion. Precursor ion scan is suited to find structural homologs of 
a selected fragment ion. In multiple reaction monitoring mode (MRM), a selected 
parent ion (Q1 mass) is fragmented within the collision cell and selected fragment 
ion analyzed by the detector. Together this series of events forms a reaction where 
multiple ions are monitored, hence the term multiple reaction monitoring.
3.3 Linear ion trap mass analyzer
The quadrupole ion trap and the related quadrupole mass filter were invented by 
Paul and Steinwedel [47]. A quadrupole ion trap (QIT or 3D-IT) mass spectrometer 
operates with a three-dimensional quadrupole field. The QIT is formed by three 
electrodes: a ring electrode with a donut shape placed symmetrically between two 
end cap electrodes. QIT is a RF only quadrupole that acts a storage device and ions 
are focused to center of trap by collision with helium gas. Motion of ions in trap is 
regulated by axial and radial frequencies. The quadrupole ion trap can store only 
a limited number of ions before space charging occurs. To circumvent this effect, 
most instruments have an automatic gain control procedure (AGC). This procedure 
exactly determines the adequate fill time of the trap to maximize sensitivity and 
minimize resolution losses due to space charge. Ion motion can be modified either 
by exciting the radial or the axial frequencies by applying a small oscillating poten-
tial at the end cap electrodes during the RF ramp. Linear ion trap enables higher 
sensitivity than triple quadrupole mass spec analyzers in full scan mode, given the 
capability of ion accumulation before traveling to the detector (Figure 7).
Figure 5. 
Schematic diagram of operation of quadrupole mass analyzer.
Figure 6. 
Schematic diagram of triple quadrupole mass analyzer.
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There are more than a few important features which impact the time neces-
sary to attain a mass spectrum (duty cycle): (i) injection time (0.5–500.0 ms), 
(ii) scan speed (5000–20,000 m/z units/s), (iii) separation of the parent ion and 
fragmentation in tandem MS or MSn. Contrarily to the triple quadrupole, MS/MS 
is not performed in space but in time. Fragmentation happens with the assistance 
of helium as collision gas. Also, duty cycles for fragmentation (MS/MS) are much 
shorter in linear ion trap when compared to triple quadrupole mass analyzer. One 
major challenge in linear ion trap is to trap precursor ion and fragment in the same 
space. Often, due to this disadvantage, fragmentation spectra generated in linear 
ion trap differs from that of triple quadrupole CID. Also, number of MRM transi-
tions that can be monitored in linear ion trap are quite less [4–8] when compared to 
QqQ mass analyzers (~100 MRM transitions can be monitored).
Due to the high sensitivity in MSn mode, ion traps are particularly attractive 
for qualitative analysis in drug metabolism, metabolomics and proteomics studies. 
Similar sensitivities to QqQ mass analyzer can be achieved for quantitative analysis 
on linear ion trap, but at the price of precision and accuracy.
While linear ion traps mainly function on radial ejection, next generation mass 
analyzers called quadrupole linear ion trap use axial ejection. This led to discovery 
of hybrid triple quadrupole mass analyzers, where Q3 performs the function of 
both quadrupole and linear ion trap [48, 49]. Unlike linear ion trap that frag-
ments precursor in time, these hybrid analyzers perform fragmentation in space. 
Figure 7. 
Schematic diagram of linear ion trap mass analyzer.
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The major advantage of this analyzer is that qualitative and quantitative analysis 
can be performed in the same LC–MS run.
3.4 Time of flight mass analyzer
Discovered in 1940’s, time of flight mass analyzers achieved popularity after 
1990’s. Time of flight operates on principle of “time that ions need to cross in a field 
free tube of about 1 m length” [50, 51]. The motion of an ion is characterized by its 
kinetic energy Ec = 0.5 m x v2 (m = mass, v = speed). Therefore, the time ions fly 
through the tube is directly proportional to their m/z value. The velocity of the ions 
formed is generally low and they are accelerated by strong electric fields (2000–
2030,000 V) in the direction of the detector. Low mass ions reach the detector 
more rapidly than high mass ions. Due to the short flight time (50–100 msec) and 
the good transmission, a spectrum can be generated within 100 ms over an almost 
unlimited mass range. Mass resolution of time of flight mass analyzer depends on 
the length of flight tube and reduced kinetic energy spread of the ions. Length of 
flight tube is directly proportional to mass resolution. Kinetic energy spread can 
be reduced by increasing time delay between ion formation and acceleration, also 
known as delayed pulse extraction. Also, positioning of electrostatic mirror in the 
drift region of ions increases the mass resolution (Figure 8).
Briefly, the ions with high energy penetrate deeper into the ion mirror region 
than those with the same m/z at a lower energy. Because of the different trajectories, 
all ions of the same m/z reach the detector at the same time. With the reflectron 
the flight path is increased without changing the physical size of the instrument. 
Commercial TOF instruments are available to operate in either linear mode or 
reflectron mode. Even though ESI can be coupled with TOF, but the combination of 
MALDI and TOF is most popular as both operate on the principle of pulsed tech-
nique. Coupling of ESI with TOF needs orthogonal acceleration to drive continuous 
beam of ions [52].
Time of flight instruments are designed to use for qualitative analysis with 
MALDI or atmospheric pressure ionization. MALDI hyphenated with time of flight 
analyzer enables the identification of large molecules such as proteins, peptides, 
lipids and polymers. MS/MS information can also be obtained by CID in drift tube 
with the assistance of nitrogen or argon as collision gas. However, as quadrupole 
Figure 8. 
Schematics representation of a quadrupole time of flight mass spectrometer.
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Figure 9. 
Schematic representation of operation of orbitrap mass analyzer.
technology is so successful for both qualitative and quantitative analysis, TOF 
analyzers are used as a hybrid platform with quadrupole analyzers. In these hybrid 
systems, TOF analyzer replaces Q3 of a triple quadrupole system. These hybrid 
systems are termed as QTOF mass spectrometers. QTOF systems offer high mass 
resolution (~40,000) and sensitivity. Accurate mass measurements are especially 
useful in metabolite identification studies and peptide analysis [53]. Various other 
hydrid TOF platforms have been reported including, linear ion trap, quadrupole ion 
trap and TOF-TOF mass spectrometers [54–56].
3.5 Orbitrap mass analyzer
Orbitrap mass analyzer operates on principle of Fourier transform, where 
orbital trapping of ions around an electrode system is achieved with the assistance 
of electrical field [57]. The orbitrap is formed by a central spindle-like electrode 
surrounded by an electrode with a barrel-like shape to create an electrostatic 
potential. The m/z is a reciprocal proportionate to the frequency of the ions oscillat-
ing along the z-axis. Detection is performed by measuring the current image of the 
axial motion of the ions around the inner electrode. The mass spectrum is obtained 
after Fourier transformation of the image current. The orbitrap provides a mass 
resolving power exceeding 100,000 and a mass accuracy ~3 ppm. To be operational 
as a mass spectrometer the orbitrap requires external ion accumulation, cooling and 
fragmentation (Figure 9).
The first commercial instrument to utilize this capability, LTQ Orbitrap Classic, 
was introduced by Thermo Fisher Scientific in 2005, which later underwent many 
innovations with the addition of a collision cell after the C-trap in LTQ Orbitrap XL, 
addition of electron transfer dissociation (ETD) capabilities, followed by MALDI 
source operating at reduced pressure with high-end LTQ Orbitrap XL MALDI 
instrument, and finally a stacked ring rf ion guide (so called S-lens) brought about 
10-fold higher transfer efficiency in the MS/MS mode.
Typically, the highest resolving powers available in TOF devices are several 
times lower than the resolution in Orbitrap, although recent multipass TOF devices 
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are capable of ultrahigh resolution (R ≥ 100,000 at m/z 400) [58, 59]. While TOF 
accompanies similar resolution in both MS and MS/MS modes, orbitrap suffers 
from low resolution in MS/MS mode. Orbitrap technology will endure to progress 
towards increased resolving power, acquisition speed, sensitivity and mass accu-
racy. These developments will indisputably open the arena for new applications as 
the Orbitrap instruments are getting more prevalent and exploring into new areas 
of research.
4. Applications in drug discovery
4.1 ADME studies
Drug discovery research was solely driven by chemists and pharmacologist 
in early 1990’s, when very little is known about drug absorption, distribution, 
metabolism and elimination (ADME). However, it did not take much time before 
researchers realized the importance of optimizing ADME properties of NCE’s for 
successfully driving drug discovery programs [60]. In this section, we highlighted 
importance of ADME in drug discovery and its relation to mass spectrometry.
Drug metabolism also known as xenobiotic biotransformation is the process by 
which lipophilic compounds gets eliminated from the body after getting converted 
to hydrophilic species that are easily filtered through kidney. While metabolism is 
desired in few cases where metabolites are the active species producing efficacy, 
there are metabolites that are toxic in nature. In such cases, where toxic by-products 
are produced, metabolism is not desired. Metabolism as a discipline drawn its first 
attention after the publication of RT Williams on Detoxification mechanisms [61].
Drug metabolism over the years with the aid of mass spectrometry technology 
has evolved in understanding the metabolic pathways of NCE’s and also to identify 
the metabolites (both desired and undesired) [62–65]. Mass spectrometry was ini-
tially hyphenated with gas chromatography to understand the metabolic behavior 
of NCE’s. Gas chromatography worked well for analyzing volatile compounds and 
its metabolites, however it did not suit for nonvolatile and thermolabile compounds. 
With the advent of liquid chromatography that can handle and separate compo-
nents without subjecting to evaporation, it became prevalent as an analytical tool 
for understanding drug metabolism in drug discovery and development [66, 67].
As a part of understanding the metabolic properties, NCE’s will be initially 
screened for metabolic stability in across species (human/rat/dog/mouse/monkey) 
and in various matrices including microsomes/S9 fractions/cytosol/hepatocytes, 
plasma, tissue homogenates, and buffer. If metabolism is not desired then com-
pounds will be screened for their stability in relevant matrices and compounds with 
moderate to high stability (defined by half-life and intrinsic clearance) are further 
optimized for additional ADME properties. Various Phase 1 metabolic reactions 
including oxidation, demethylation, hydroxylation and phase 2 metabolic reactions 
covering glucuronidation, sulfation, methylation, amino acids conjugation and glu-
tathione conjugation can be quantitatively and qualitatively studied using LC–MS/
MS. Additionally, for compounds that are unstable, understanding the soft spots 
responsible for instability helps medicinal chemists to make relevant structural 
modifications in order to stabilize the unstable compounds. Understanding the soft 
spots precisely, needs the assistance of high-resolution mass spectrometry instru-
ments such as TOF and Orbitrap. With the accurate mass information obtained 
from these mass spec’s, identifying a metabolite structure will be spot on.
Similarly, other in vitro parameters such as permeability, protein binding, 
solubility, lipophilicity, CYP inhibition and CYP induction also play a key role in 
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drug disposition [15, 68, 69]. All of these assays have high sensitivity requirements 
and demand quantification of analytes within a few nanomolar range. For example, 
in case of permeability assessment, low permeable compounds such as atenolol 
permeate poorly from apical to basolateral side complicates the quantification of the 
apparent permeability values, if analyzed with low sensitive detectors. Likewise, 
fraction unbound values for highly protein compounds such as warfarin were such 
low that it demands highly sensitive detectors to accurately quantify such low levels. 
Needless to mention that all of the assays performed to optimize ADME properties 
of NCE’s require highly sensitive detection systems. Hence, with its superior detec-
tion sensitivity, mass spectrometer has become an indispensable tool to understand 
the in vitro ADME properties of NCE’s.
As discussed in the previous sections, even though there exist many ionization 
techniques, atmospheric pressure ionization (API) was more successful in drug 
metabolism studies, given its rapid, specific and sensitive methodologies for the 
identification of drugs and its metabolites. Mass spectrometer instruments types 
used in ADME studies vary from those that provide nominal mass information and 
accurate mass information. Nominal mass instruments such as triple quadrupoles 
are useful for quantitative applications, whereas accurate mass instruments includ-
ing QTOF and Orbitrap are used for both quantitative and qualitative applications.
Of the atmospheric pressure ionization techniques available, ESI and APCI 
are the most commonly used. While APCI can accommodate high flow rates and 
produce high sensitivity, nevertheless analytes are subjected to higher temperatures 
in the evaporation process and hence as an ionization technique is not suitable for 
thermolabile (esp. glucuronides, N-oxides and sulfates) compounds. However, ESI 
is comparatively a soft ionization technique and could efficiently ionize these fragile 
compounds without degradation. As a whole, mass spectrometer exhibits both 
qualitative and quantitative applications in drug metabolism studies. However, in 
case of other ADME battery of assays as described above, mass spectrometer is used 
majorly for quantitative applications.
4.2 Metabolite identification
Metabolite identification (Met-ID) provides a variety of inputs in drug discovery 
and development which includes in vitro metabolite profiling in early stages of 
lead identification/optimization, followed by in vitro/in vivo correlation in late 
stage lead identification, characterization of putative metabolites, cross-species 
comparison to identify the right tox preclinical species, understanding drug–drug 
interactions, and identifying pharmacologically active or toxic metabolites and the 
mechanisms by which they are formed [70, 71].
Met-ID is quite challenging when it comes to a) identification of vast number of 
diverse metabolites, b) metabolites that are of low abundance, and c) high through-
put analytical requirements to screen majority of early leads in preclinical drug 
discovery [72]. Even though there exist various platforms such as triple quadrupole, 
linear ion trap, and Qtrap to quantitatively/qualitatively identify metabolites, they 
turned obsolete due to nominal mass information they generate and are no longer 
valuable [73].
The term mass resolution is used to describe the mass resolving power accord-
ing to the degree to which two analytes with close m/z values can be separated and 
identified. A practical and convenient way of evaluating the mass resolution of 
an instrument is the use of the full width at half maximum (FWHM) definition 
in which the m/z/Δm/z ratio is calculated, where m/z is the mass-to-charge value 
of an ion peak and Δm/z is the full width at half the maximal height of the peak. 
Nominal mass instruments generate resolution in low thousands (1000–4000), 
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which cannot separate isobaric ions with similar nominal m/z value. However, high 
resolution mass spectrometers provide resolution in the range of higher thousands 
(10000–100,000), that successfully identify and separate isobaric ions (Figure 10).
For a given nominal mass, there exists many possible molecular structures for 
an assigned biotransformation pathway. Hence, for an accurate molecular structure 
the metabolite has to be scaled up in larger quantities and measured using NMR 
spectroscopy. However, scaling up metabolites to “mg” quantities need tremendous 
efforts, resources and is not an economical approach. Later, with the discovery of 
high-resolution mass spectrometers such as TOF and Orbitrap, that provides accu-
rate mass to the fourth decimal, enabled accurate prediction of molecular structures 
of metabolites [74–79].
In principle, as long as data can be measured accurately, high-resolution data is 
sufficient to demonstrate the presence or absence of defined species. Apart from 
high resolution masses, modern mass spectrometers also generate data with higher 
accuracy. The term mass accuracy is used to define how close the mass measured 
by the mass spectrometer is to the theoretical exact mass of an ion. Mass accuracy 
Figure 10. 
Increased resolution separating two closely arranged analytes with similar nominal m/z values.
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is typically expressed as a relative mass error using the ratio of the difference 
between the experimental and theoretical m/z values over the theoretical m/z 
value of an ion.
Metabolite identification studies are typically performed in full scan mode (or) 
data dependent scan mode. In full scan mode, accurate mass information of parent 
ions is studied to understand the biotransformation pathways. However, to propose 
soft spots for metabolites, data dependent scans consisting of combination of full 
scan and product ion scans are performed. Metabolites in general can be considered 
as off springs to the parent molecular ions that carry similar fragments as that 
of parent ion (or) neutral loss fragments. In case of similar fragments to that of 
parent ion, these fragments can be considered unmodified and are similar to that 
of parent. Whereas, if the fragment ions are accompanied by a mass change for a 
given biotransformation pathway, then metabolite soft spot can be proposed with 
precision to that fragment ion (for example, in case of hydroxylation, neutral loss 
fragment in metabolite carries an additional mass of 16 amu) [80]. Additionally, 
apart from fragmentation scans accompanied with full scan, few other specific 
dependent scans consisting of neutral loss scan, and precursor ion scans are used to 
study various biotransformation pathways including glucuronidation, glutathione 
conjugation, sulfation (for example, glucuronidation is accompanied by a specific 
neutral loss of 176 da and glutathione conjugation by a neutral loss of 129 da in 
positive mode) [81, 82]. These specific scan functions are helpful in eliminating the 
background noise and identify the metabolites that exist even at lower abundance.
One major challenge in metabolite identification using LC–MS technology, is 
quantifying the relative abundance of metabolites. As mass spec quantitation is 
accompanied by many source/gas and compound dependent parameters that aid 
in the efficient ionization and detection, minor modifications in the metabolite 
structures alter the sensitivity by few orders of magnitude. Hence, quantitative 
results using mass spectrometer for the metabolites for which synthetic standards 
are not available, is not feasible. Additionally, it is difficult to synthesize each and 
every metabolite and determine their concentrations accurately. Alternatively, 
few researchers used LC-UV hyphenated with mass spectrometer to measure the 
relative abundance of metabolites. However, as majority of metabolites exist in 
low abundance, it becomes difficult to measure their relative abundance by UV 
spectroscopy. Also, UV is prone to differences in analytical sensitivities with minor 
modifications in structure. Hence, future mass spectrometers need to be designed 
to address these key concerns and facilitate evaluation of both quantitative and 
qualitative aspects of metabolites.
4.3 Pharmacokinetic analysis
Screening paradigm in drug discovery includes evaluation of compounds for 
their ADME properties by various in vitro assays. The datasets obtained from these 
assays help in rationalizing the synthetic chemistry efforts and make progress 
towards a pool of lead compounds that exhibit promising in vitro ADME proper-
ties. However, in vitro screening consists of unique assay platforms that can only 
answer a specific question of interest and can never cover all aspects of complex 
biological systems. Hence, it warrants the screening of selected lead compounds in 
preclinical species such as rats, mice, dog, pig and monkey, before progressing to 
clinic [83, 84]. Role of LC–MS/MS in performing bioanalysis of pharmacokinetic 
samples was well reported in the literature [85–88].
Design of pharmacokinetic studies varies from single route administration 
with few sampling points followed by multiple route administration with detailed 
time course evaluation. Samples of various natures ranging from blood, plasma, 
15
Mass Spectrometry as a Workhorse for Preclinical Drug Discovery: Special Emphasis on Drug…
DOI: http://dx.doi.org/10.5772/intechopen.88385
serum are collected to analyze the systemic concentration levels. Additionally, to 
understand the tissue distribution of compounds, various tissues including liver, 
intestine, brain, spinal cord, heart, lungs, kidneys, skin and adipose tissue are also 
analyzed. Initially, lead compounds are dosed intravenously to understand the 
disposition parameters such as volume of distribution, clearance, half-life and mean 
residence time. Compounds that possess decent pharmacokinetic parameters in 
intravenous route are further evaluated in alternate (enteral and parenteral) routes 
to assess bioavailability and exposure parameters (Cmax, Tmax, AUC0-last). To 
determine plasma concentrations as low as “ng” levels, sensitive analytical detectors 
are needed. HPLC-UV detector systems are proven robust for analyzing concentra-
tions at higher “μg” level. However, as UV detection is not specific, it suffers from 
high background noise when biological samples are analyzed. High background 
noise in turn causes quantitation issues at the lower portion of calibration curve. On 
the other hand, LC–MS/MS detection system is considered to be highly specific and 
selective, as background noise can be eliminated by analyzing selected analytes of 
interest with desired m/z ratios. Also, mass spectrometric detection is considered 
highly sensitive than UV spectroscopic detection. Altogether, these advanced 
features, enabled LC–MS/MS to overcome the limitations of UV detection and is 
more frequently used in drug discovery and development for the bioanalysis of 
pharmacokinetic samples.
Of the various mass spectrometers available in the market, triple quadrupole 
LC–MS/MS systems have demonstrated tremendous success when it comes to 
quantitative applications. Monitoring specific reaction transitions that consist of 
parent and fragment ion, with associated source/gas and compound dependent 
parameters makes the mass spectrometer highly specific, selective and sensitive. 
Pharmacokinetic study samples are in general monitored for plasma concentrations 
over the time profile and hence triple quadrupole systems have achieved greater 
success. However, exploratory studies performed to understand metabolic pattern 
and biotransformation mechanisms of NCE’s again need the assistance of linear 
ion traps and high-resolution mass spectrometer platforms (Orbitrap and TOF). 
As pharmacokinetic study samples are of biological origin and complex in nature, 
extracts obtained after sample preparation complicate the bioanalysis on LC–MS/
MS. This phenomenon in broad terms is termed as Matrix effects. Causes of matrix 
effects and strategies to mitigate these effects are discussed in detail in the succeed-
ing section.
Typically, pharmacokinetic studies are performed by administering a single test 
item in preclinical species. However, screening of single test item is labor intensive, 
not economical and demand higher turn-around times to generate pharmacokinetic 
data. Hence, researchers have come up with an alternate strategy, where a pool of 
compounds are administered in single dose, a technique well-known as cassette dos-
ing or N-in-one dosing. The foundation for designing cassette dosing strategy comes 
from the ability of LC–MS/MS to analyze multiple test items without any chromato-
graphic separation [89–92]. However, disadvantages with cassette dosing include 
altered pharmacokinetics due to drug–drug interaction potential, non-feasibility 
of pooling compounds with close molecular weights and compounds with differing 
physicochemical properties posing formulatability issues. Compounds with differing 
physicochemical properties comes with a challenge of formulating the selected pool 
of compounds in a single formulation vehicle. While issues with physicochemical 
properties and close molecular weights can be taken care of, drug–drug interaction 
appears to be of a major concern. One approach to minimize DDI’s is by administer-
ing the compounds at minimal doses, collectively not exceeding the dose of single 
test item administration [93]. Also, dosing volumes can be kept as low as possible. 
Additionally, along with pool of unknown compounds, a quality control compound 
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with known pharmacokinetic parameters can be administered. Pharmacokinetic 
study results of unknown compounds can be considered acceptable, as long as qual-
ity control compounds fall within the set acceptance criteria. Compounds with less 
than 5 da difference in molecular weight are difficult to pool, when triple quadrupole 
systems are used for analyzing the pharmacokinetic samples. However, this chal-
lenge can be overcome by considering high resolution mass spectrometric analysis. 
Typical pharmacokinetic parameters studied from intravenous administration 
include half-life (t1/2), clearance (Cl), volume of distribution (Vz), mean residence 
time (MRT), area under the curve (AUC0-last; AUC0-inf), whereas parameters such as 
Cmax, Tmax and area under the curve are studies in other routes of administration. 
When compounds are dosed in multiple routes, along with intravenous route of 
administration, absolute bioavailability values are calculated.
Current fast LC–MS/MS instruments enable analysis of mixture of analytes 
with minimal separation, shorter run times and also feasible for hyphenation with 
ultra-fast liquid chromatography systems. Additionally, latest LC–MS/MS systems 
are capable of analyzing thousands of samples every week due to higher loading 
capacity of samples in autosampler, shorter run times and introduction of 96/384 
well plate formats.
Test samples are analyzed against a calibration curve and a set of quality control 
samples. Calibration curve consists of 8–10 known standards and quality controls 
span the calibration curve at a minimum of 3 levels. Typical accuracy limits for 
qualifying the calibration and quality control samples is set as ±20%. Typical turn-
around times for execution of pharmacokinetic studies right from dosing initiation 
to generation of pharmacokinetic parameters spans 1–2 weeks. Importance of high 
throughput bioanalysis and its role in drug discovery is discussed in detail in the 
section below.
4.4 High throughput bioanalysis
With the combinatorial chemistry efforts leading to synthesis of hundreds of 
compounds in early phases of drug discovery, there is a constant need for analytical 
platforms that can quickly churn out data and help in accelerating the discovery 
process. LC–MS/MS with proven track record as a reliable analytical platform had 
undergone evolutionary changes to support high throughput demands of drug 
discovery [60, 70, 87, 94–96]. These strategies include advancements in chromato-
graphic columns, where lower dimensions and microbore HPLC columns cut short 
run time to one minute per sample. Quick sample run times help in analyzing higher 
number of samples with in the given stipulated time [97]. Faster gradient methods 
with LC pumps that can handle higher pressure also enable analysis with shorter run 
times [98]. With the invention of monolithic HPLC columns that can be operated at 
high flow rates in the order of 5–6 mL/min, analytical run times were significantly 
reduced [99–101]. One disadvantage of these columns is that the high flow rates 
translate in to higher usage of mobile phase, making it an expensive alternative.
Another approach for increasing sample throughput is by the use of parallel 
HPLC columns, where the effluent from two HPLC systems could be combined and 
assayed by using the MRM/SRM capabilities of the MS/MS system [102, 103]. One 
more approach in enhancing the throughput is through staggered analysis approach. 
Here, multiple HPLC columns are used, but the injection time is staggered such that 
the “analytical window” can be selected sequentially in order to maximize the use 
of the MS/MS system and increase sample throughput [104].
On the other hand, throughput can also be increased by pooling of samples, 
provided the sensitivity is not seriously compromised. When these samples are 
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analyzed on triple quadrupole systems, care must be taken to have molecular weight 
differences by at least 5 da. Typically, 4–5 analytes can be pooled and analyzed. 
Only challenge with pooling/cassette strategy (even with high resolution mass 
spectrometers) is its non-suitability for isomeric compounds. With advancements 
in instrumentation technology, modern LC autosamplers are designed to accom-
modate higher sample load. There are autosamplers that can accommodate as high 
as twelve 96 well plates. Higher loading capacity of autosamplers enable unattended 
analysis of large number of samples (Figure 11).
When it comes to sample preparation, robotic platforms can be used to screen 
larger pool of compounds across various in vitro assays. However, this strategy 
can also be used for processing of in vivo samples, provided if the sample cohort is 
higher. In general, automated robotic sample preparation platforms are quite often 
used for screening of compounds in in vitro assays. These robotic platforms help 
in decreasing the manpower involved and time taken for performing the assays. 
However, main disadvantage with robotic platforms is the need for preparation 
of larger volumes of reagents and the cost factor involved. Hence, it is not recom-
mended to use these platforms unless there exists a larger library of compounds.
4.5 Matrix effects
With the sample nature being biological in origin, supernatants obtained after 
sample preparation consists of many endogenous components that compete with 
the analyte of interest and result in either suppression/enhancement of ionization. 
This process of alteration of the ionization of analytes is termed as matrix effects. 
The “matrix” refers to all components in the sample other than analyte(s) of inter-
est. Matrix effects are defined as “interference from matrix components that are 
Figure 11. 
Pictorial representation of LC–MS/MS system with higher loading capacity of autosampler.
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unrelated to the analyte” [105, 106]. The process of ion suppression/enhancement is 
in general referred as matrix effect and is main subject of various published reviews 
[107–112].Matrix effects result in significant deviation in precision and accuracy of 
results which in turn debate the reliability of pharmacokinetic parameters of NCE’s 
generated. Matrix effect alters the sensitivity, reproducibility and challenges the 
reliability of analytical techniques. Although matrix effects occur as a result of vari-
ous exogenous and endogenous components, one major area of concern is formula-
tion excipients (an exogenous component) used in the preparation of formulations. 
Dosing vehicles are generally used at high concentrations to solubilize test articles 
of highly lipophilic nature [113–115]. This in turn can be instrumental in causing 
matrix effects, thereby questioning the reliability of preclinical PK parameters. This 
phenomenon has been reported by us in the past for various excipients such as PEG 
400 [110, 116, 117], Cremophor EL [111, 118] and Solutol HS15 [112, 119].
Several mechanisms have been proposed to explain matrix effects, but the exact 
process remains uncertain [120, 121]. Various mechanisms by which matrix compo-
nents cause ion suppression are as follows:
• Charge competition between analyte and matrix components [122, 123].
• Change in droplet surface tension leading to formation of large droplets and 
insufficient desolvation [121, 124].
• Preferential ion evaporation due to matrix components gathering at droplet 
surface.
• Change in mass of analyte ion due to ion pairing and adduct formation
• Co-precipitation with non-volatile matrix components [125].
• Gas phase deprotonation.
Reduction of matrix effects can be achieved through various strategies includ-
ing decreasing the level of matrix components, improving chromatographic 
separation of interfering materials from the analyte, various sample preparation 
strategies, lower injection volumes, and even by simple dilution of samples to 
reduce the overall concentrations of both analyte and co-extracted materials [126, 
127]. Switching ionization sources will also help in mitigating the matrix effects 
[112, 116, 118, 119]. Matrix effects occurring in the early time point samples can 
be monitored, using another aliquot of the early time point samples analyzed at a 
higher dilution [128].
5. Conclusion
Over the past few decades, technological advancements in mass spectrometer 
enabled it to surpass other detection platforms and evolve as an indispensable ana-
lytical tool to support the bioanalytical needs of drug discovery and development. 
Current generation mass spectrometers could efficiently handle both qualitative 
and quantitative aspects of bioanalysis. Additionally, the likelihood of hyphenation 
of mass spectrometers with ultrafast liquid chromatography systems, extended its 
applications to high throughput bioanalysis. Even though significant achievements 
were made in the past, instruments will continue to get more and more sensitive 
and become better acquiescent to automation.
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